Business
Notice of Half-Year Results
Notice of Half-Year Results.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n Sareum Holdings PLC\n \n \n \n \n \n (\"Sareum\" or the \"Company\")\n \n \n \n \n \n \n Notice of Half-Year Results and Investor Presentation\n \n \n \n \n \n \n \n Cambridge, UK, 15 March 2023\n \n - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, will announce its unaudited results for the six months ended 31 December 2022 on Wednesday, 22 March 2023.\n \n \n \n \n \n The Company will be holding a presentation to investors on Wednesday, 22 March 2023 at 12.30 pm GMT via the Investor Meet Company (\"IMC\") platform.\n \n \n \n \n \n Investors can sign up to Investor Meet Company for free and add to meet SAREUM HOLDINGS PLC via:\n \n https://www.investormeetcompany.com/sareum-holdings-plc/register-investor\n \n \n \n \n \n \n Investors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.\n \n \n \n \n \n A copy of the presentation will be made available on the Company's website following the presentation.\n \n \n \n - Ends -\n \n \n \n \n \n \n \n For further information, please contact: \n \n \n \n \n \n \n \n Sareum Holdings plc\n \n \n Tim Mitchell, CEO\n \n \n Alexandra Harrison,\n Head of IR\n \n \n \n \n \n \n \n \n \n \n 01223 497700\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n Strand Hanson Limited (Nominated Adviser)\n \n \n James Dance / James Bellman\n \n \n \n \n \n \n \n \n \n \n 020 7409 3494\n \n \n \n \n \n \n Peel Hunt LLP (Joint Corporate Broker)\n \n \n James Steel / Oliver Duckworth\n \n \n \n \n \n \n \n \n \n \n 020 7418 8900\n \n \n \n \n \n \n Hybridan LLP (Joint Corporate Broker)\n \n \n Claire Noyce\n \n \n \n \n \n \n \n \n \n \n 020 3764 2341\n \n \n \n \n \n \n Consilium Strategic Communications (Financial PR)\n \n \n Jessica Hodgson / Davide Salvi / Stella Lempidaki\n \n \n \n \n \n \n \n 0203 709 5700\n \n \n \n \n \n \n \n \n \n \n About Sareum\n \n \n \n Sareum (AIM: SAR) is a\n biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.\n \n \n The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and h...